An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Butterfly Network to Present at the 40th Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Butterfly Network, Inc. (NYSE: BFLY) will participate in the 40th Annual J.P. Morgan Healthcare Conference virtually from January 10-13, 2022. Dr. Todd Fruchterman, the President and CEO, will present on January 11, 2022, at 2:15 PM ET. A live webcast and archived recording will be accessible on the Butterfly investor website. Butterfly Network, founded in 2011, is known for its innovative handheld ultrasound technology aimed at improving global health equity, providing ultrasound access to 4.7 billion people worldwide.
Positive
None.
Negative
None.
GUILFORD, Conn. & NEW YORK--(BUSINESS WIRE)--
Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly"), today announced that it will participate in the 40th Annual J.P. Morgan Healthcare Conference to be held virtually on January 10-13, 2022. Dr. Todd Fruchterman, President and CEO will present virtually on Tuesday, January 11, 2022, at 2:15 pm Eastern Time.
A live webcast of the presentation and an archived recording will be available in the Events & Presentations section of the Butterfly Network investor website.
About Butterfly Network, Inc. Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network has created the world’s first handheld, single-probe whole-body ultrasound system using its patented Ultrasound-on-Chip™ semiconductor technology. Butterfly’s mission is to democratize medical imaging and contribute to the aspiration of global health equity, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ and Butterfly iQ+ Vet can be purchased today by healthcare practitioners and veterinarians, respectively, in the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, and the United Kingdom. Butterfly iQ+ is a prescription device intended for qualified healthcare professionals only. For more information, visit www.butterflynetwork.com.